Stent length as a potential indicator to select patients who may benefit from long-term dual antiplatelet therapy

摘要

6- to 12-month dual antiplatelet therapy (DAPT), combining aspirin and a P2Y_12 receptor inhibitor, is currently the recommended treatment for patients with an acute coronary syndrome and those who underwent percutaneous coronary interventions (PCI) with drug-eluting stent (DES) implantation 1. Thereafter, patients should be switched to single antiplatelet therapy (namely aspirin) and this treatment must be pursued lifelong in outpatients with stable coronary artery disease (CAD) 2.However, the optimal duration of DAPT following coronary stenting is today a great matter of debate. Some authors have suggested individual adaptation of the duration of DAPT after PCI and that 'one duration may not fit all'.